Registration number:
Umedica Laboratories UK Ltd
for the Year Ended 31 March 2026
Umedica Laboratories UK Ltd
Contents
|
Company Information |
|
|
Balance Sheet |
|
|
Notes to the Financial Statements |
Umedica Laboratories UK Ltd
Company Information
|
Directors |
Mr Simon Michael Aylott Mr Pratik Mohit Kothari |
|
Registered office |
|
|
Auditors |
|
Umedica Laboratories UK Ltd
(Registration number: 15920788)
Balance Sheet as at 31 March 2026
|
Note |
2026 |
2025 |
|
|
Fixed assets |
|||
|
Tangible assets |
|
|
|
|
Current assets |
|||
|
Debtors |
|
|
|
|
Cash at bank and in hand |
|
|
|
|
|
|
||
|
Creditors: Amounts falling due within one year |
( |
( |
|
|
Net current assets |
|
|
|
|
Total assets less current liabilities |
|
|
|
|
Creditors: Amounts falling due after more than one year |
( |
- |
|
|
Net assets |
|
|
|
|
Capital and reserves |
|||
|
Called up share capital |
100,000 |
10,000 |
|
|
Retained earnings |
9,121 |
- |
|
|
Shareholders' funds |
109,121 |
10,000 |
Approved and authorised by the
|
......................................... |
......................................... |
Umedica Laboratories UK Ltd
Notes to the Financial Statements for the Year Ended 31 March 2026
|
General information |
The company is a private company limited by share capital, incorporated in England and Wales.
The address of its registered office is:
England
These financial statements were authorised for issue by the
|
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
The company's functional and presentation currency is UK Sterling.
Going concern
The financial statements have been prepared on a going concern basis.
Audit report
The name of the Senior Statutory Auditor who signed the audit report on
Revenue recognition
The Company provides sales and marketing support and administrative support services to its parent company under a service agreement. Revenue is recognised as the services are provided and measured at the amount recoverable under the agreement, being the costs incurred in providing the services plus a 5% mark-up. Revenue is recognised on an accruals basis as the customer simultaneously receives and consumes the benefits of the services provided. Any transfer pricing year-end adjustments are recognised when agreed and measurable. Revenue is presented net of VAT.
Umedica Laboratories UK Ltd
Notes to the Financial Statements for the Year Ended 31 March 2026
Tax
The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.
Tangible assets
Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.
Depreciation
Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:
|
Asset class |
Depreciation method and rate |
|
Computer equipment |
WDV and 3 years estimated useful life |
Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.
Trade debtors
Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.
Trade creditors
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.
Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.
Umedica Laboratories UK Ltd
Notes to the Financial Statements for the Year Ended 31 March 2026
Financial instruments
Classification
Debt instruments (other than those wholly repayable or receivable within one year), including loans and other debtors and creditors, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method.
Debt instruments that are payable or receivable within one year, typically trade creditors or debtors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration, expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms of financed at a rate of interest that is not a market rate or in case of an out-right short term loan not at a market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.
Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss if recognised in the Profit and loss account.
For financial assets measured as amortised cost, the impairment loss is measured as the difference between an asset’s carrying amount and the present value of estimated cash flows discounted at the asset’s original effective interest rate. If a financial asset has a variable interest rate, the discounted rate for measuring any impairment loss is the current effective interest rate determined under the contract.
For financial assets measured as cost less impairment, the impairment loss is measured as the difference between an asset’s carrying amount and best estimate, which is an approximation of the amount that the company would receive for the asset if it were to be sold at the balance sheet date.
Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
|
Staff numbers |
The average number of persons employed by the company (including directors) during the year, was
Umedica Laboratories UK Ltd
Notes to the Financial Statements for the Year Ended 31 March 2026
|
Tangible assets |
|
Computer equipment |
Total |
|
|
Cost or valuation |
||
|
At 1 April 2025 |
|
|
|
At 31 March 2026 |
|
|
|
Depreciation |
||
|
At 1 April 2025 |
|
|
|
Charge for the year |
|
|
|
At 31 March 2026 |
|
|
|
Carrying amount |
||
|
At 31 March 2026 |
|
|
|
At 31 March 2025 |
|
|
|
Debtors |
|
Current |
Note |
2026 |
2025 |
|
Amounts owed by related parties |
- |
|
|
|
Other debtors |
|
- |
|
|
|
|
Umedica Laboratories UK Ltd
Notes to the Financial Statements for the Year Ended 31 March 2026
|
Creditors |
Creditors: amounts falling due within one year
|
2026 |
2025 |
||
|
Due within one year |
|||
|
Trade creditors |
|
|
|
|
Other creditors |
|
- |
|
|
Accrued expenses |
|
|
|
|
Corporation tax payable |
|
- |
|
|
|
|
||
|
Due after one year |
|||
|
Other financial liabilities |
|
- |
|
Share capital |
Allotted, called up and fully paid shares
|
2026 |
2025 |
|||
|
No. |
£ |
No. |
£ |
|
|
|
|
100,000 |
|
10,000 |
During the year, 90,000 ordinary shares were issued at par.
|
Related party transactions |
The company has taken advantage of the exemptions available in FRS 102 Section 1A from disclosing related party transactions with other companies that are wholly owned within the group.
Umedica Laboratories UK Ltd
Notes to the Financial Statements for the Year Ended 31 March 2026
|
Parent and ultimate parent undertaking |
The company's immediate and ultimate parent is
The most senior parent entity producing publicly available financial statements is
P. No-221, 222/1,
GIDC,
Vapi,
Valsad,
Pardi - 396195,
Gujarat,
India.